Reviva Common Stock vs Short Term Debt Analysis

RVPH Stock

USD 1.37 0.03 2.24%

Reviva Pharmaceuticals financial indicator trend analysis is much more than just breaking down Reviva Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Reviva Pharmaceuticals is a good investment. Please check the relationship between Reviva Pharmaceuticals Common Stock and its Short Term Debt accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Reviva Pharmaceuticals Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.

Common Stock vs Short Term Debt

Common Stock vs Short Term Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Reviva Pharmaceuticals Common Stock account and Short Term Debt. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Reviva Pharmaceuticals' Common Stock and Short Term Debt is -0.44. Overlapping area represents the amount of variation of Common Stock that can explain the historical movement of Short Term Debt in the same time period over historical financial statements of Reviva Pharmaceuticals Holdings, assuming nothing else is changed. The correlation between historical values of Reviva Pharmaceuticals' Common Stock and Short Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock of Reviva Pharmaceuticals Holdings are associated (or correlated) with its Short Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Term Debt has no effect on the direction of Common Stock i.e., Reviva Pharmaceuticals' Common Stock and Short Term Debt go up and down completely randomly.

Correlation Coefficient

-0.44

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Common Stock

Short Term Debt

Most indicators from Reviva Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Reviva Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Reviva Pharmaceuticals Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.

The Reviva Pharmaceuticals' current Enterprise Value is estimated to increase to about 60.9 M, while Tax Provision is projected to decrease to 9,973.

	2021	2022	2023	2024 (projected)
Tax Provision	6.0K	20.8K	16.9K	10.0K
Income Tax Expense	6.0K	20.8K	23.9K	25.1K

Tax Provision Income Tax Expense

Reviva Pharmaceuticals fundamental ratios Correlations

	Other Current Liab	Total Current Liabilities	Net Tangible Assets	Retained Earnings	Accounts Payable	Other Assets	Total Current Assets	Common Stock	Property Plant Equipment	Total Assets	Short Long Term Debt Total	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross
Other Current Liab		0.66	0.86	-0.94	0.94	0.62	0.86	0.9	-0.71	0.88	-0.74	0.75	-0.74	-0.87	0.89	-0.97	-0.74	0.87	0.84	0.94	-0.74	-0.93	0.92	0.65	0.81	0.89
Total Current Liabilities	0.66		0.28	-0.85	0.73	0.04	0.27	0.47	-0.24	0.32	-0.9	0.06	-0.9	-0.25	0.33	-0.48	-0.9	0.27	0.34	0.61	-0.9	-0.36	0.61	1.0	0.16	0.4
Net Tangible Assets	0.86	0.28		-0.72	0.75	0.77	0.95	0.83	-0.84	0.96	-0.5	0.95	-0.5	-0.98	0.97	-0.94	-0.5	0.96	0.95	0.81	-0.5	-0.95	0.75	0.26	0.99	0.98
Retained Earnings	-0.94	-0.85	-0.72		-0.96	-0.38	-0.69	-0.83	0.62	-0.72	0.86	-0.52	0.86	0.68	-0.73	0.84	0.86	-0.69	-0.76	-0.89	0.86	0.77	-0.86	-0.84	-0.63	-0.8
Accounts Payable	0.94	0.73	0.75	-0.96		0.33	0.68	0.86	-0.68	0.71	-0.77	0.55	-0.77	-0.71	0.73	-0.86	-0.77	0.69	0.8	0.88	-0.77	-0.8	0.83	0.72	0.68	0.84
Other Assets	0.62	0.04	0.77	-0.38	0.33		0.88	0.57	-0.56	0.88	-0.22	0.9	-0.22	-0.87	0.86	-0.76	-0.22	0.88	0.62	0.6	-0.22	-0.8	0.61	0.03	0.8	0.63
Total Current Assets	0.86	0.27	0.95	-0.69	0.68	0.88		0.87	-0.79	1.0	-0.41	0.95	-0.41	-0.98	1.0	-0.95	-0.41	1.0	0.91	0.87	-0.41	-0.98	0.84	0.26	0.95	0.89
Common Stock	0.9	0.47	0.83	-0.83	0.86	0.57	0.87		-0.75	0.86	-0.44	0.7	-0.44	-0.83	0.87	-0.91	-0.44	0.86	0.91	0.98	-0.44	-0.92	0.96	0.46	0.8	0.84
Property Plant Equipment	-0.71	-0.24	-0.84	0.62	-0.68	-0.56	-0.79	-0.75		-0.79	0.38	-0.76	0.38	0.8	-0.79	0.78	0.38	-0.79	-0.85	-0.71	0.38	0.8	-0.64	-0.2	-0.83	-0.84
Total Assets	0.88	0.32	0.96	-0.72	0.71	0.88	1.0	0.86	-0.79		-0.47	0.95	-0.47	-0.99	1.0	-0.96	-0.47	1.0	0.91	0.87	-0.47	-0.98	0.84	0.3	0.96	0.91
Short Long Term Debt Total	-0.74	-0.9	-0.5	0.86	-0.77	-0.22	-0.41	-0.44	0.38	-0.47		-0.32	1.0	0.46	-0.48	0.61	1.0	-0.43	-0.46	-0.57	1.0	0.49	-0.54	-0.89	-0.39	-0.61
Total Stockholder Equity	0.75	0.06	0.95	-0.52	0.55	0.9	0.95	0.7	-0.76	0.95	-0.32		-0.32	-0.98	0.94	-0.88	-0.32	0.96	0.83	0.69	-0.32	-0.91	0.64	0.05	0.97	0.87
Current Deferred Revenue	-0.74	-0.9	-0.5	0.86	-0.77	-0.22	-0.41	-0.44	0.38	-0.47	1.0	-0.32		0.46	-0.48	0.61	1.0	-0.43	-0.46	-0.57	1.0	0.49	-0.54	-0.89	-0.39	-0.61
Net Debt	-0.87	-0.25	-0.98	0.68	-0.71	-0.87	-0.98	-0.83	0.8	-0.99	0.46	-0.98	0.46		-0.99	0.96	0.46	-0.99	-0.9	-0.82	0.46	0.98	-0.78	-0.23	-0.98	-0.93
Cash	0.89	0.33	0.97	-0.73	0.73	0.86	1.0	0.87	-0.79	1.0	-0.48	0.94	-0.48	-0.99		-0.97	-0.48	1.0	0.92	0.88	-0.48	-0.98	0.85	0.31	0.96	0.92
Non Current Assets Total	-0.97	-0.48	-0.94	0.84	-0.86	-0.76	-0.95	-0.91	0.78	-0.96	0.61	-0.88	0.61	0.96	-0.97		0.61	-0.96	-0.9	-0.93	0.61	0.99	-0.9	-0.47	-0.91	-0.93
Non Currrent Assets Other	-0.74	-0.9	-0.5	0.86	-0.77	-0.22	-0.41	-0.44	0.38	-0.47	1.0	-0.32	1.0	0.46	-0.48	0.61		-0.43	-0.46	-0.57	1.0	0.49	-0.54	-0.89	-0.39	-0.61
Cash And Short Term Investments	0.87	0.27	0.96	-0.69	0.69	0.88	1.0	0.86	-0.79	1.0	-0.43	0.96	-0.43	-0.99	1.0	-0.96	-0.43		0.91	0.86	-0.43	-0.98	0.83	0.26	0.96	0.9
Common Stock Total Equity	0.84	0.34	0.95	-0.76	0.8	0.62	0.91	0.91	-0.85	0.91	-0.46	0.83	-0.46	-0.9	0.92	-0.9	-0.46	0.91		0.87	-0.46	-0.91	0.8	0.32	0.93	0.96
Common Stock Shares Outstanding	0.94	0.61	0.81	-0.89	0.88	0.6	0.87	0.98	-0.71	0.87	-0.57	0.69	-0.57	-0.82	0.88	-0.93	-0.57	0.86	0.87		-0.57	-0.92	0.99	0.6	0.77	0.83
Short Term Investments	-0.74	-0.9	-0.5	0.86	-0.77	-0.22	-0.41	-0.44	0.38	-0.47	1.0	-0.32	1.0	0.46	-0.48	0.61	1.0	-0.43	-0.46	-0.57		0.49	-0.54	-0.89	-0.39	-0.61
Non Current Liabilities Total	-0.93	-0.36	-0.95	0.77	-0.8	-0.8	-0.98	-0.92	0.8	-0.98	0.49	-0.91	0.49	0.98	-0.98	0.99	0.49	-0.98	-0.91	-0.92	0.49		-0.89	-0.35	-0.94	-0.92
Other Stockholder Equity	0.92	0.61	0.75	-0.86	0.83	0.61	0.84	0.96	-0.64	0.84	-0.54	0.64	-0.54	-0.78	0.85	-0.9	-0.54	0.83	0.8	0.99	-0.54	-0.89		0.61	0.7	0.75
Total Liab	0.65	1.0	0.26	-0.84	0.72	0.03	0.26	0.46	-0.2	0.3	-0.89	0.05	-0.89	-0.23	0.31	-0.47	-0.89	0.26	0.32	0.6	-0.89	-0.35	0.61		0.14	0.37
Net Invested Capital	0.81	0.16	0.99	-0.63	0.68	0.8	0.95	0.8	-0.83	0.96	-0.39	0.97	-0.39	-0.98	0.96	-0.91	-0.39	0.96	0.93	0.77	-0.39	-0.94	0.7	0.14		0.95
Property Plant And Equipment Gross	0.89	0.4	0.98	-0.8	0.84	0.63	0.89	0.84	-0.84	0.91	-0.61	0.87	-0.61	-0.93	0.92	-0.93	-0.61	0.9	0.96	0.83	-0.61	-0.92	0.75	0.37	0.95

Click cells to compare fundamentals

Reviva Pharmaceuticals Account Relationship Matchups

Reviva Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Other Current Liab	101.5K	324.7K	1.8M	2.5M	2.9M	3.0M
Total Current Liabilities	6.8M	1.3M	2.3M	6.0M	17.2M	18.0M
Net Tangible Assets	(35.9M)	7.4M	28.7M	12.3M	14.2M	14.9M
Retained Earnings	(54.5M)	(58.3M)	(66.8M)	(91.2M)	(134.4M)	(127.6M)
Accounts Payable	224.5K	1.0M	509.6K	3.5M	3.8M	4.0M
Total Current Assets	193.0	8.8M	31.4M	18.9M	23.7M	15.2M

Currently Active Assets on Macroaxis

V	Visa Class A
BAC	Bank of America
GM	General Motors
GOOG	Alphabet Inc Class C
CRM	Salesforce

When determining whether Reviva Pharmaceuticals is a strong investment it is important to analyze Reviva Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Reviva Pharmaceuticals' future performance. For an informed investment choice regarding Reviva Stock, refer to the following important reports:

How To Invest In Reviva

Details

Is Reviva Stock a good investment?

Details

What is Reviva Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Reviva Pharmaceuticals Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.

You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.

Complementary Tools for Reviva Stock analysis

When running Reviva Pharmaceuticals' price analysis, check to measure Reviva Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Reviva Pharmaceuticals is operating at the current time. Most of Reviva Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Reviva Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Reviva Pharmaceuticals' price. Additionally, you may evaluate how the addition of Reviva Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules
	CEOs Directory Screen CEOs from public companies around the world
	Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences
	Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk
	My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios
	Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
	Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas

Is Reviva Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Reviva Pharmaceuticals. If investors know Reviva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Reviva Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.43)

Return On Assets

(1.16)

Return On Equity

(5.56)

The market value of Reviva Pharmaceuticals is measured differently than its book value, which is the value of Reviva that is recorded on the company's balance sheet. Investors also form their own opinion of Reviva Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Reviva Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Reviva Pharmaceuticals' market value can be influenced by many factors that don't directly affect Reviva Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Reviva Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Reviva Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Reviva Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Reviva Common Stock vs Short Term Debt Analysis

Common Stock vs Short Term Debt

Common Stock vs Short Term Debt Correlation Analysis

Correlation Coefficient

Common Stock

Short Term Debt

Reviva Pharmaceuticals fundamental ratios Correlations

Reviva Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Reviva Pharmaceuticals fundamental ratios Accounts

Currently Active Assets on Macroaxis

Complementary Tools for Reviva Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 1.0	Total Current Liabilities
Total Assets	+ 1.0	Total Current Assets
Cash	+ 1.0	Total Current Assets
Cash And Short Term Investments	+ 1.0	Total Current Assets
Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets

Cash And Short Term Investments	- 0.99	Net Debt
Cash	- 0.99	Net Debt
Net Debt	- 0.99	Total Assets
Non Current Liabilities Total	- 0.98	Cash And Short Term Investments
Non Current Liabilities Total	- 0.98	Cash
Net Invested Capital	- 0.98	Net Debt